Refractory MMN: What Treatment Options Are Available?

When Intravenous Immunoglobulin (IVIg) seems to provide less benefit than it once did, it can be deeply frustrating. If your symptoms are returning after a period of stability, this decline may reflect a “wearing-off” effect between treatments, disease progression, fixed nerve damage, or even a different underlying medical issue ^[1][2].

Your specialist will likely start by re-evaluating your diagnosis and reviewing your current IVIg regimen. If optimizing IVIg is not appropriate or effective, they may discuss supportive care or clinical trials for emerging therapies, as traditional second-line immune drugs generally lack strong evidence for Multifocal Motor Neuropathy (MMN) ^[3][4]. Do not change your IVIg dose, interval, or stop your treatment without consulting your neurologist, as doing so can worsen your symptoms ^[5]. Seek urgent care if you experience rapidly progressive weakness, inability to stand, or new trouble breathing or swallowing, as these are not typical for MMN and require immediate assessment.

1. Re-evaluating the Diagnosis and Nerve Health

Before changing treatments, your neurologist will likely perform a clinical exam and possibly nerve conduction studies (EMG) to understand why your strength has declined ^[6].

• Checking for other causes: A change in symptoms does not automatically mean IVIg has permanently failed. Doctors must rule out other causes of weakness, such as spinal compression, medication side effects, or a change in the diagnosis itself (such as other neuropathies or motor neuron diseases) ^[2][7].
• Conduction Block vs. Axonal Loss: Early in MMN, weakness is primarily caused by conduction block—a reversible disruption of the nerve’s electrical signal ^[8]. Over time, however, MMN can lead to secondary axonal degeneration (permanent damage to the inner nerve fiber itself) ^[9][10]. While some recovery might still happen through surviving nerves, substantial axonal damage generally makes it harder for IVIg to restore lost strength ^[11]. In these cases, physical and occupational therapy become critical active treatments for managing the disease and maximizing function.

2. Adjusting Your Current Immunoglobulin Regimen

If the diagnosis remains MMN, your doctor may consider adjusting how you receive immunoglobulin, carefully balancing potential benefits with risks ^[12].

• Changing the Schedule: Some patients experience a “wearing-off” effect, where strength predictably dips in the days or weeks before the next infusion. For these patients, receiving smaller doses more frequently may help produce a more consistent grip strength response ^[1][13].
• Increasing the Dose: In highly individualized cases, doctors might cautiously increase the total monthly dose of IVIg ^[14]. However, a higher dose is not automatically better and may not help if axonal loss has occurred. Increasing IVIg also raises the risk of side effects, including severe headaches, kidney injury, and dangerous blood clots (thrombosis) ^[15].
• Subcutaneous Immunoglobulin (SCIg): SCIg is administered under the skin rather than into a vein. It is primarily used as a maintenance option for patients whose symptoms are already stable on IVIg, rather than a rescue treatment for new weakness ^[16][5]. Some patients switch to SCIg to avoid systemic IVIg side effects or venous access issues, but SCIg commonly causes local injection-site swelling and pain, and it requires training to self-administer ^[17][18].

3. The Limits of Traditional Immunosuppressants

If adjusting IVIg is not an option, you might wonder about immunosuppressants (drugs that lower the body’s overall immune response). Unfortunately, these are generally not recommended or are ineffective for typical MMN ^[5]:

• Mycophenolate mofetil: A randomized clinical trial found that adding this drug did not show a statistically significant improvement in strength or reduce IVIg requirements ^[3].
• Rituximab: Evidence for rituximab in MMN is limited to small, mixed case reports, meaning it is not a routine standard of care ^[19][20].
• Cyclophosphamide: While there is rare case-level evidence of this drug being used, it is not a standard treatment because it carries major risks, including severe bladder bleeding, infection, infertility, and later cancer risk ^[21].
• Corticosteroids and Plasma Exchange: These are generally not effective for MMN, and corticosteroids may actually worsen the condition in some patients ^[22][5].

4. Looking to the Future: Clinical Trials

Because older therapies fall short, research is focusing on newer, highly targeted investigational drugs ^[23].

A major focus of current MMN research involves the complement system (a specific part of the immune system). In many patients, MMN is thought to be driven by IgM antibodies (a type of immune protein, such as anti-GM1) that inappropriately activate the complement cascade, leading to nerve damage ^[4][24]. It is important to note that not all patients test positive for these antibodies, and complement activation is a proposed mechanism, not a proven complete explanation for every patient’s condition.

Investigational drugs known as complement inhibitors (like ARGX-117 and eculizumab) are designed to block this process ^[4][23]. While these drugs have shown biological activity in laboratory models, they do not yet have established human efficacy or safety evidence for MMN and are not approved treatments. Participating in a clinical trial may involve receiving a placebo, facing unknown side effects, and undertaking significant travel or time commitments.

If your condition is progressing despite optimized IVIg, you and your specialist can discuss whether exploring a clinical trial or focusing on active supportive care (like orthoses, physical therapy, and home adaptations) is the best path forward for your specific situation.